You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections

Ashkenazi, Shai MD, MSc*; Vertruyen, Andre MD†; Arístegui, Javier MD‡; Esposito, Susanna MD§; McKeith, David Douglas MBChB, MRCGP¶; Klemola, Timo MD∥; Biolek, Jiri MD#; Kühr, Joachim MD**; Bujnowski, Tadeusz MD, PhD††; Desgrandchamps, Daniel MD‡‡; Cheng, Sheau-Mei PhD§§; Skinner, Jonathan PhD§§; Gruber, William C. MD§§; Forrest, Bruce D. MB, BS, MD§§; for the CAIV-T Study Group

Pediatric Infectious Disease Journal:
doi: 10.1097/01.inf.0000237829.66310.85
Original Studies
Abstract

Background: Young children have a high incidence of influenza and influenza-related complications. This study compared the efficacy and safety of cold-adapted influenza vaccine, trivalent (CAIV-T) with trivalent inactivated influenza vaccine (TIV) in young children with a history of recurrent respiratory tract infections (RTIs).

Methods: Children 6 to 71 months of age were randomized to receive 2 doses of CAIV-T (n = 1101) or TIV (n = 1086), 35 ± 7 days apart before the start of the 2002–2003 influenza season and were followed up for culture-confirmed influenza, effectiveness outcomes, reactogenicity, and adverse events.

Results: Overall, 52.7% (95% confidence interval [CI] = 21.6%–72.2%) fewer cases of influenza caused by virus strains antigenically similar to vaccine were observed in CAIV-T than in TIV recipients. Greater relative efficacy for CAIV-T was observed for the antigenically similar A/H1N1 (100.0%; 95% CI = 42.3%–100.0%) and B (68.0%; 95% CI = 37.3%–84.8%) strains but not for the antigenically similar A/H3N2 strains (−97.1%; 95% CI = −540.2% to 31.5%). Relative to TIV, CAIV-T reduced the number of RTI-related healthcare provider visits by 8.9% (90% CI = 1.5%–15.8%) and missed days of school, kindergarten, or day care by 16.2% (90% CI = 10.4%–21.6%). Rhinitis and rhinorrhea, otitis media, and decreased appetite were the only events that were reported more frequently in CAIV-T subjects. There was no difference between groups in the incidence of wheezing after vaccination.

Conclusions: CAIV-T was well tolerated in these children with RTIs and demonstrated superior relative efficacy compared with TIV in preventing influenza illness.

Author Information

From the *Schneider Children's Medical Center, Petah-Tikva, Israel; †Sâint Vincentius Hospital, Antwerp, Belgium; ‡Hospital de Basurto, Bilbao, Spain; §Institute of Paediatrics, University of Milan, Fondazione IRCCS “Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena,” Milan, Italy; ¶Townhead Surgery, Irvine, UK; ∥Jorvi Hospital, University of Helsinki, Espoo, Finland; #Hospital Most, Most, Czech Republic; **Clinic for Paediatric and Adolescent Medicine (Stadt Klinikrum Karlsruhe), Karlsruhe, Germany; ††Gabinet Prywatny, Skierniewice, Poland; ‡‡Children's Hospital, Lucerne, Switzerland; and §§Wyeth Vaccines Research, Pearl River, NY.

Accepted for publication July 14, 2006.

This study was funded by Wyeth Vaccines Research and MedImmune.

Address for correspondence: Shai Ashkenazi, MD, MSc, Schneider Children's Medical Center, Department of Pediatrics A, 14 Kaplan St, Petah-Tikva 49202, Israel. E-mail sashkenazi@clalit.org.il or ashai@post.tau.ac.il.

© 2006 Lippincott Williams & Wilkins, Inc.